Last reviewed · How we verify

Treatment by clopidogrel

University Hospital, Bordeaux · Phase 1 active Small molecule Quality 8/100

Treatment by clopidogrel is a Small molecule drug developed by University Hospital, Bordeaux. It is currently in Phase 1 development.

At a glance

Generic nameTreatment by clopidogrel
SponsorUniversity Hospital, Bordeaux
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Treatment by clopidogrel

What is Treatment by clopidogrel?

Treatment by clopidogrel is a Small molecule drug developed by University Hospital, Bordeaux.

Who makes Treatment by clopidogrel?

Treatment by clopidogrel is developed by University Hospital, Bordeaux (see full University Hospital, Bordeaux pipeline at /company/university-hospital-bordeaux).

What development phase is Treatment by clopidogrel in?

Treatment by clopidogrel is in Phase 1.

What are the side effects of Treatment by clopidogrel?

Common side effects of Treatment by clopidogrel include Epistaxis, Dyspnoea, Haematoma, Haematuria, Gingival Bleeding, Hypertension.

Related